INO-3107

Product

Last mentioned: Mar 18, 2026

Timeline

  1. PDUFA Date

    Target date for FDA decision on INO-3107 accelerated approval.

  2. Platform Modernization

    LivePerson expects to complete its multiyear platform modernization.

  3. BLA Acceptance

    FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.

  4. Inovio Cash Position

    Company ends the year with $94.1 million in cash.

Stories mentioning INO-3107 1

health-it Neutral

Inovio Faces FDA Hurdle for INO-3107 as LivePerson Scales Enterprise AI

Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.

3 sources